Eli Lilly Q4 Revenue Up 43%, Guides $80–83B, Gets $1,350 Price Target
Eli Lilly reported Q4 revenue of $19.3 billion, up 43% year-over-year, and non-GAAP EPS of $7.54, powered by Zepbound’s $4.2 billion U.S. sales (122% growth). Barclays initiated coverage at Overweight with a $1,350 price target implying 28% upside and guided 2026 revenue to $80–83 billion, forecasting roughly 25% growth.
1. Barclays Initiates Overweight Rating
Barclays launched coverage on U.S. large-cap biopharma with a Neutral sector view, naming Eli Lilly as an Overweight top pick and setting a $1,350 price target, implying 28% upside from current levels. The firm cited Lilly’s scale in AI-driven drug discovery and deep clinical pipeline as key advantages.
2. Q4 2025 Results and 2026 Guidance
Eli Lilly’s Q4 revenue reached $19.3 billion, up 43% year-over-year, with non-GAAP EPS of $7.54, driven by Zepbound’s $4.2 billion U.S. sales (122% growth) and robust Mounjaro demand. Management guided 2026 revenue to $80–83 billion, forecasting roughly 25% growth.
3. TD Cowen Conference Presentation
Eli Lilly presented at the TD Cowen 46th Annual Health Care Conference, highlighting its AI-enabled drug discovery efforts and progress across late-stage pipeline programs, reinforcing confidence in its growth trajectory.